How the Psybrary™ Could Revolutionize Psychedelic Drug Discovery


Ryan Allway

September 28th, 2020

App, Exclusive, Psychedelics, Top Story


The psychedelic drug market is projected to grow at a compound annual growth rate of 16.3% over the next eight years to reach $6.85 billion by 2026, according to Data Bridge Market Research. With the potential to treat a wide range of mental health disorders, several organizations are already conducting clinical trials in the space.

Let’s take a look at MagicMed’s Psybrary™, the current stage of development and how it could revolutionize psychedelic drug discovery.

What is the Psybrary™?

MagicMed’s Psybrary™ is a portfolio of psychedelic molecules and the patents that protect them. While the company is focused on psychedelic drug discovery, the goal is to license these molecules to biotech or pharmaceutical companies for clinical development (where it will earn milestone payments), and ultimately, commercialization (where it will earn royalties).

MagicMed CEO Dr. Joseph Tucker explains its proprietary Psybrary™

The company combines synthetic biology—or taking enzymes from nature and using them to make modifications to molecules—with classic chemistry to create thousands of novel psychedelic molecules. These molecules are protected by both composition of matter and method of manufacturing patents to build a robust and defensible portfolio.

Click here to learn more about investing in MagicMed and receive corporate updates

With years of experience in developing innovative production methods for plant-derived pharmaceuticals, the company has built a strong foundation of novel molecules based on psilocybin and ayahuasca. Management is ready to work with commercial partners to commercialize these molecules while pursuing new molecules based on MDMA, ketamine, ibogaine and other types of psychedelic molecules over the next 12 months.

A Unique Business Model

MagicMed’s management team is focused on psychedelic drug discovery—the first part of the drug development process. With experience in developing opiates, cannabinoids and ephedra derivatives, the company is uniquely positioned to leverage its decades of experience and proprietary methods in the psychedelic industry.

CEO Dr. Joseph Tucker discussed present and future opportunities for business partners

Dr. Peter Facchini has published more than 160 scientific papers and holds 20 patents in the molecular derivatives field. Meanwhile, Dr. Jillian Hagel has held COO and VP roles across the biotech industry where she was instrumental in building patent portfolios and coordinating partnerships to drive significant long-term value for shareholders.

The company’s business model is unique because, once it develops a new molecule—which it is doing for thousands of molecules—there’s little additional capital costs. By licensing the molecule, the company shifts the risk of development and commercialization to another business while retaining milestone payments and potential royalties on sales.

Click here to learn more about investing in MagicMed and receive corporate updates

Looking Ahead

MagicMed Industries is uniquely positioned to capitalize on the growing demand for psychedelic treatments for various mental illnesses. With its innovative business model, shareholders could benefit from a diverse range of high-margin recurring revenue streams.

The company hopes to onboard its first partner this year while targeting a public listing during the first or second quarter of next year when it achieves a positive cash flow. In 2022, management hopes to start receiving milestone payments and potentially diversify into the large and growing licit consumer goods industry.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading